Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Acquisitions & Divestments (2016 - 2020)

Cumberland Pharmaceuticals (CPIX) has disclosed Change in Acquisitions & Divestments for 9 consecutive years, with -$460888.0 as the latest value for Q4 2020.

  • Quarterly Change in Acquisitions & Divestments fell 110.53% to -$460888.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Sep 2020, down 69.17% year-over-year, with the annual reading at $20.1 million for FY2019, 24.44% up from the prior year.
  • Change in Acquisitions & Divestments hit -$460888.0 in Q4 2020 for Cumberland Pharmaceuticals, down from $460888.0 in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $9.2 million in Q3 2018 to a low of -$460888.0 in Q4 2020.
  • Historically, Change in Acquisitions & Divestments has averaged $3.2 million across 5 years, with a median of $2.1 million in 2016.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 972.73% in 2017 and later plummeted 110.53% in 2020.
  • Year by year, Change in Acquisitions & Divestments stood at $812366.0 in 2016, then surged by 359.95% to $3.7 million in 2017, then soared by 146.71% to $9.2 million in 2018, then tumbled by 52.53% to $4.4 million in 2019, then tumbled by 110.53% to -$460888.0 in 2020.
  • Business Quant data shows Change in Acquisitions & Divestments for CPIX at -$460888.0 in Q4 2020, $460888.0 in Q3 2020, and $4.4 million in Q4 2019.